DE29623606U1 - Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenol-Verbindungen aus Grüntee-Extrakt - Google Patents

Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenol-Verbindungen aus Grüntee-Extrakt

Info

Publication number
DE29623606U1
DE29623606U1 DE29623606U DE29623606U DE29623606U1 DE 29623606 U1 DE29623606 U1 DE 29623606U1 DE 29623606 U DE29623606 U DE 29623606U DE 29623606 U DE29623606 U DE 29623606U DE 29623606 U1 DE29623606 U1 DE 29623606U1
Authority
DE
Germany
Prior art keywords
health
therapeutically effective
green tea
tea extract
polyphenol compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE29623606U
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitasyn GmbH
Original Assignee
Vitasyn GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitasyn GmbH filed Critical Vitasyn GmbH
Priority to DE29623606U priority Critical patent/DE29623606U1/de
Priority claimed from DE19627344A external-priority patent/DE19627344A1/de
Publication of DE29623606U1 publication Critical patent/DE29623606U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
DE29623606U 1996-07-01 1996-07-01 Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenol-Verbindungen aus Grüntee-Extrakt Expired - Lifetime DE29623606U1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE29623606U DE29623606U1 (de) 1996-07-01 1996-07-01 Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenol-Verbindungen aus Grüntee-Extrakt

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19627344A DE19627344A1 (de) 1996-07-01 1996-07-01 Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenolverbindungen
DE29623606U DE29623606U1 (de) 1996-07-01 1996-07-01 Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenol-Verbindungen aus Grüntee-Extrakt

Publications (1)

Publication Number Publication Date
DE29623606U1 true DE29623606U1 (de) 1999-06-10

Family

ID=26027284

Family Applications (1)

Application Number Title Priority Date Filing Date
DE29623606U Expired - Lifetime DE29623606U1 (de) 1996-07-01 1996-07-01 Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenol-Verbindungen aus Grüntee-Extrakt

Country Status (1)

Country Link
DE (1) DE29623606U1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1236477A2 (de) 2001-02-28 2002-09-04 MG Pharmacy Ltd. Synthese Baustein fur Proteinkomplexe
WO2002039956A3 (en) * 2000-11-15 2003-02-20 Univ Rutgers Black tea extract for prevention of disease

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039956A3 (en) * 2000-11-15 2003-02-20 Univ Rutgers Black tea extract for prevention of disease
EP1236477A2 (de) 2001-02-28 2002-09-04 MG Pharmacy Ltd. Synthese Baustein fur Proteinkomplexe
EP1236477A3 (de) * 2001-02-28 2004-06-16 MG Pharmacy Ltd. Synthese Baustein fur Proteinkomplexe
US7026284B2 (en) 2001-02-28 2006-04-11 Bmg Incorporated Formative agent of protein complex

Similar Documents

Publication Publication Date Title
EP1196043A4 (de) Formulierung eines aufschaeumenden gruenen tee extraktes
DE69707079D1 (de) Löslicher Espresso Kaffee
ES2177506T3 (es) Extractos de te verde que contienen catecoles y cafeina.
AU2000278445A1 (en) Tea catechin formulations and processes for making same
ATE240657T1 (de) Macchiato-kaffeekonzentratsystem
ZA200106683B (en) Method for the preparation of citalopram.
GR3036569T3 (en) Process for extraction of polyphenolic compounds of catechin type from plants, the so obtained extract and its use
EP1328283A4 (de) Topisches hautpräparat mit kieferpollen oder kieferpollenextrakt
DE29623606U1 (de) Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenol-Verbindungen aus Grüntee-Extrakt
HUP9901538A3 (en) Drink from plant extract
DE29704023U1 (de) Kaffeekochvorrichtung
DE29619678U1 (de) Gerät zur Teezubereitung
GB9906919D0 (en) Herbal tobacco (tobacco substitute)
AU2001289070A1 (en) Coffee roaster
HU9802843D0 (en) Extract from pepper
ES1029662Y (es) Filtro de porcion para cafe tostado.
DE29819590U1 (de) Grüntee Konzentrat
ZA956793B (en) Preparation of aromatic aldehydes.
KR970026597U (ko) 커피콩 볶음기
DE29610310U1 (de) Teebeutelausdrücker
HU9904431D0 (en) Extract from pepper
DE29619224U1 (de) Filtereinrichtung zur Herstellung von Aromaauszügen aus Kaffee oder Tee
BR9605562A (pt) Aparelho de fazer chá
TW424426U (en) Improved shriveling device for tea leaves
TW439411U (en) Improved structure for automatically moving in-and-out the placement frames for drying tea leaves

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 19990722

R150 Utility model maintained after payment of first maintenance fee after three years

Effective date: 20000301

R151 Utility model maintained after payment of second maintenance fee after six years

Effective date: 20030124

R152 Utility model maintained after payment of third maintenance fee after eight years

Effective date: 20050201

R071 Expiry of right